Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate PTK787/ZK 222584, a drug that blocks new blood
vessel growth, in the treatment of patients with non-metastatic androgen independent prostate
cancer. This study will assess the safety and tolerability of PTK787/ZK 222584, and evaluate
serum vascular endothelial growth factor (VEGF) levels.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center